<DOC>
	<DOCNO>NCT01904058</DOCNO>
	<brief_summary>The study randomize , double-blind , placebo-controlled , multicenter study . It 13-week Phase 2 study adult primary biliary cirrhosis design compare effect daily dose UDCA combination LUM001 placebo .</brief_summary>
	<brief_title>Phase 2 Study Evaluate LUM001 Combination With Ursodeoxycholic Acid Patients With Primary Biliary Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Liver Cirrhosis , Biliary</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<criteria>1 . Diagnosis Primary Biliary Cirrhosis 2 . Moderate severe pruritus 3 . Taking ursodeoxycholic acid ( UDCA ) least 6 month , unable tolerate UDCA 4 . Ability understand willingness sign inform consent prior initiation study procedures 1 . History presence concomitant significant liver disease 2 . Liver transplant 3 . Known HIV infection 4 . Women pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>PBC</keyword>
</DOC>